SEGMENT INFORMATION (Tables)

6 Months Ended

Apr. 30, 2015

Segment Reporting [Abstract]

Segment Profitability and Segment Assets

The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below.

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Three months ended April 30, 2015:
Total net revenue	$	473	$	169	$	321	$	963
Segment income from operations	$	75	$	25	$	69	$	169
Three months ended April 30, 2014:
Total net revenue	$	495	$	168	$	325	$	988
Segment income from operations	$	71	$	26	$	70	$	167

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Six months ended April 30, 2015:
Total net revenue	$	1,020	$	317	$	652	$	1,989
Segment income from operations	$	182	$	26	$	137	$	345
Six months ended April 30, 2014:
Total net revenue	$	1,032	$	325	$	639	$	1,996
Segment income from operations	$	176	$	45	$	139	$	360

The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. During the second quarter of 2015 we changed the segment asset allocation methodology to more closely represent the use of assets by each segment following a review of operational metrics. Accordingly the segment assets presented as of October 31, 2014 have been restated to follow the new methodology.

	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Assets:
As of April 30, 2015	$	1,548	$	2,028	$	1,005	$	4,581
As of October 31, 2014	$	1,663	$	2,302	$	1,001	$	4,966

Reconciliation of segment results to total enterprise results

The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes:

	Three Months Ended						Six Months Ended
	April 30,						April 30,
	2015			2014			2015			2014
	(in millions)
Total reportable segments’ income from operations	$	169		$	167		$	345		$	360
Acceleration of share-based compensation related to workforce reduction	(1		)	—			(2		)	—
Transformational initiatives	(17		)	(8		)	(29		)	(11		)
Amortization of intangibles	(38		)	(49		)	(81		)	(98		)
Acquisition and integration costs	(1		)	(2		)	(2		)	(8		)
Business exit and divestiture costs (primarily our NMR business)	(8		)	—			(11		)	—
Pre-separation costs	—			(2		)	—			(4		)
Other	3			(2		)	2			(1		)
Interest income	2			2			4			4
Interest expense	(17		)	(30		)	(33		)	(59		)
Other income (expense), net	4			3			16			3
Unallocated corporate charges	—			(10		)	—			(20		)
Income from continuing operations before taxes, as reported	$	96		$	69		$	209		$	166